Annual Total Long Term Liabilities
$822.50 M
+$83.42 M+11.29%
December 31, 2023
Summary
- As of February 25, 2025, BCRX annual total long term liabilities is $822.50 million, with the most recent change of +$83.42 million (+11.29%) on December 31, 2023.
- During the last 3 years, BCRX annual total long term liabilities has risen by +$574.18 million (+231.22%).
- BCRX annual total long term liabilities is now at all-time high.
Performance
BCRX Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Long Term Liabilities
$806.25 M
-$12.71 M-1.55%
September 30, 2024
Summary
- As of February 25, 2025, BCRX quarterly total long term liabilities is $806.25 million, with the most recent change of -$12.71 million (-1.55%) on September 30, 2024.
- Over the past year, BCRX quarterly long term liabilities has stayed the same.
- BCRX quarterly long term liabilities is now -4.38% below its all-time high of $843.15 million, reached on September 30, 2023.
Performance
BCRX Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Long Term Liabilities Formula
Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities
BCRX Long Term Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +11.3% | 0.0% |
| 3 y3 years | +231.2% | +188.8% |
| 5 y5 years | +2824.0% | +1526.0% |
BCRX Long Term Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +39.1% | -4.4% | +36.3% |
| 5 y | 5-year | at high | +1740.3% | -4.4% | +2516.7% |
| alltime | all time | at high | >+9999.0% | -4.4% | >+9999.0% |
BioCryst Pharmaceuticals Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $806.25 M(-1.6%) |
| Jun 2024 | - | $818.96 M(-0.6%) |
| Mar 2024 | - | $824.14 M(+0.2%) |
| Dec 2023 | $822.50 M(+11.3%) | $822.50 M(-2.4%) |
| Sep 2023 | - | $843.15 M(+2.2%) |
| Jun 2023 | - | $825.10 M(+9.6%) |
| Mar 2023 | - | $752.87 M(+1.9%) |
| Dec 2022 | $739.08 M(+25.0%) | $739.08 M(+2.7%) |
| Sep 2022 | - | $719.62 M(+14.5%) |
| Jun 2022 | - | $628.38 M(+2.9%) |
| Mar 2022 | - | $610.92 M(+3.3%) |
| Dec 2021 | $591.42 M(+138.2%) | $591.42 M(+111.8%) |
| Sep 2021 | - | $279.20 M(+4.3%) |
| Jun 2021 | - | $267.76 M(+3.7%) |
| Mar 2021 | - | $258.22 M(+4.0%) |
| Dec 2020 | $248.32 M(+455.6%) | $248.32 M(+705.9%) |
| Sep 2020 | - | $30.81 M(-13.3%) |
| Jun 2020 | - | $35.55 M(-11.7%) |
| Mar 2020 | - | $40.24 M(-10.0%) |
| Dec 2019 | $44.70 M(+58.9%) | $44.70 M(-9.9%) |
| Sep 2019 | - | $49.58 M(-7.5%) |
| Jun 2019 | - | $53.59 M(+0.2%) |
| Mar 2019 | - | $53.51 M(+90.2%) |
| Dec 2018 | $28.13 M(+43.1%) | $28.13 M(-9.5%) |
| Sep 2018 | - | $31.08 M(+90.8%) |
| Jun 2018 | - | $16.29 M(-9.4%) |
| Mar 2018 | - | $17.98 M(-8.5%) |
| Dec 2017 | $19.66 M(-42.0%) | $19.66 M(-9.1%) |
| Sep 2017 | - | $21.62 M(-29.1%) |
| Jun 2017 | - | $30.50 M(-6.0%) |
| Mar 2017 | - | $32.43 M(-4.4%) |
| Dec 2016 | $33.91 M(+173.9%) | $33.91 M(-5.8%) |
| Sep 2016 | - | $35.99 M(+184.8%) |
| Jun 2016 | - | $12.64 M(+5.2%) |
| Mar 2016 | - | $12.01 M(-2.9%) |
| Dec 2015 | $12.38 M(+213.7%) | $12.38 M(+18.3%) |
| Sep 2015 | - | $10.47 M(+1.4%) |
| Jun 2015 | - | $10.32 M(+184.0%) |
| Mar 2015 | - | $3.63 M(-7.9%) |
| Dec 2014 | $3.95 M(-88.6%) | $3.95 M(+2.5%) |
| Sep 2014 | - | $3.85 M(-44.6%) |
| Jun 2014 | - | $6.95 M(-80.4%) |
| Mar 2014 | - | $35.42 M(+2.0%) |
| Dec 2013 | $34.74 M(-14.6%) | $34.74 M(-5.1%) |
| Sep 2013 | - | $36.61 M(-1.1%) |
| Jun 2013 | - | $37.01 M(-3.7%) |
| Mar 2013 | - | $38.41 M(-5.5%) |
| Dec 2012 | $40.67 M(-1.1%) | $40.67 M(-2.6%) |
| Sep 2012 | - | $41.75 M(+0.7%) |
| Jun 2012 | - | $41.47 M(+1.7%) |
| Mar 2012 | - | $40.77 M(-0.8%) |
| Dec 2011 | $41.10 M(+157.8%) | $41.10 M(-12.8%) |
| Sep 2011 | - | $47.14 M(-0.1%) |
| Jun 2011 | - | $47.19 M(+0.8%) |
| Mar 2011 | - | $46.83 M(+193.7%) |
| Dec 2010 | $15.94 M(-14.6%) | $15.94 M(-4.9%) |
| Sep 2010 | - | $16.76 M(-3.7%) |
| Jun 2010 | - | $17.40 M(-3.5%) |
| Mar 2010 | - | $18.03 M(-3.4%) |
| Dec 2009 | $18.67 M | $18.67 M(-3.3%) |
| Sep 2009 | - | $19.31 M(-3.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2009 | - | $19.95 M(-2.8%) |
| Mar 2009 | - | $20.52 M(-3.0%) |
| Dec 2008 | $21.16 M(-57.4%) | $21.16 M(-54.8%) |
| Sep 2008 | - | $46.78 M(-2.3%) |
| Jun 2008 | - | $47.88 M(-2.2%) |
| Mar 2008 | - | $48.98 M(-1.4%) |
| Dec 2007 | $49.69 M(+35.8%) | $49.69 M(-2.2%) |
| Sep 2007 | - | $50.81 M(-2.1%) |
| Jun 2007 | - | $51.93 M(+28.7%) |
| Mar 2007 | - | $40.34 M(+10.2%) |
| Dec 2006 | $36.60 M(+24.4%) | $36.60 M(-1.8%) |
| Sep 2006 | - | $37.27 M(-1.4%) |
| Jun 2006 | - | $37.80 M(-0.5%) |
| Mar 2006 | - | $38.00 M(+29.1%) |
| Dec 2005 | $29.43 M(+9708.7%) | $29.43 M(+9708.7%) |
| Sep 2005 | - | $300.00 K(0.0%) |
| Jun 2005 | - | $300.00 K(0.0%) |
| Mar 2005 | - | $300.00 K(0.0%) |
| Dec 2004 | $300.00 K(0.0%) | $300.00 K(0.0%) |
| Sep 2004 | - | $300.00 K(0.0%) |
| Jun 2004 | - | $300.00 K(0.0%) |
| Mar 2004 | - | $300.00 K(0.0%) |
| Dec 2003 | $300.00 K(0.0%) | $300.00 K(0.0%) |
| Sep 2003 | - | $300.00 K(0.0%) |
| Jun 2003 | - | $300.00 K(0.0%) |
| Mar 2003 | - | $300.00 K(0.0%) |
| Dec 2002 | $300.00 K(0.0%) | $300.00 K(0.0%) |
| Sep 2002 | - | $300.00 K(0.0%) |
| Jun 2002 | - | $300.00 K(0.0%) |
| Mar 2002 | - | $300.00 K(0.0%) |
| Dec 2001 | $300.00 K(-94.3%) | $300.00 K(0.0%) |
| Sep 2001 | - | $300.00 K(0.0%) |
| Jun 2001 | - | $300.00 K(-93.4%) |
| Mar 2001 | - | $4.52 M(-13.4%) |
| Dec 2000 | $5.22 M(+1641.2%) | $5.22 M(+1641.2%) |
| Sep 2000 | - | $300.00 K(0.0%) |
| Jun 2000 | - | $300.00 K(-0.9%) |
| Mar 2000 | - | $302.70 K(+0.9%) |
| Dec 1999 | $300.00 K(0.0%) | $300.00 K(0.0%) |
| Sep 1999 | - | $300.00 K(0.0%) |
| Jun 1999 | - | $300.00 K(-25.0%) |
| Mar 1999 | - | $400.00 K(+33.3%) |
| Dec 1998 | $300.00 K(0.0%) | $300.00 K(0.0%) |
| Sep 1998 | - | $300.00 K(-25.0%) |
| Jun 1998 | - | $400.00 K(+33.3%) |
| Mar 1998 | - | $300.00 K(0.0%) |
| Dec 1997 | $300.00 K(0.0%) | $300.00 K(-25.0%) |
| Sep 1997 | - | $400.00 K(0.0%) |
| Jun 1997 | - | $400.00 K(0.0%) |
| Mar 1997 | - | $400.00 K(+33.3%) |
| Dec 1996 | $300.00 K(-57.1%) | $300.00 K(-25.0%) |
| Sep 1996 | - | $400.00 K(-20.0%) |
| Jun 1996 | - | $500.00 K(0.0%) |
| Mar 1996 | - | $500.00 K(-28.6%) |
| Dec 1995 | $700.00 K(-12.5%) | $700.00 K(+16.7%) |
| Sep 1995 | - | $600.00 K(-25.0%) |
| Jun 1995 | - | $800.00 K(0.0%) |
| Mar 1995 | - | $800.00 K(0.0%) |
| Dec 1994 | $800.00 K | $800.00 K(-20.0%) |
| Sep 1994 | - | $1.00 M(0.0%) |
| Jun 1994 | - | $1.00 M(-9.1%) |
| Mar 1994 | - | $1.10 M |
FAQ
- What is BioCryst Pharmaceuticals annual total long term liabilities?
- What is the all time high annual total long term liabilities for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals annual total long term liabilities year-on-year change?
- What is BioCryst Pharmaceuticals quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals quarterly long term liabilities year-on-year change?
What is BioCryst Pharmaceuticals annual total long term liabilities?
The current annual total long term liabilities of BCRX is $822.50 M
What is the all time high annual total long term liabilities for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high annual total long term liabilities is $822.50 M
What is BioCryst Pharmaceuticals annual total long term liabilities year-on-year change?
Over the past year, BCRX annual total long term liabilities has changed by +$83.42 M (+11.29%)
What is BioCryst Pharmaceuticals quarterly total long term liabilities?
The current quarterly long term liabilities of BCRX is $806.25 M
What is the all time high quarterly long term liabilities for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high quarterly total long term liabilities is $843.15 M
What is BioCryst Pharmaceuticals quarterly long term liabilities year-on-year change?
Over the past year, BCRX quarterly total long term liabilities has changed by $0.00 (0.00%)